

**InterGenetics Research on OncoVue Published in *CANCER*, Journal of the American Cancer Society, Identifies Age-Specific Genetic Associations Involved in Determining Breast Cancer Risk**

**OncoVue<sup>®</sup>, First Genetic-Based Breast Cancer Risk Detection Test to Determine Risk based on DNA and a Woman's Personal Medical History**

**For Immediate Release:**

May 16, 2007

**Oklahoma City** –A key part of the science used to develop OncoVue, the first genetic-based, breast cancer risk test applicable to all women, is featured in the May publication of one of America's premier research journals "*CANCER*", the Journal of the American Cancer Society.

"The focus of this paper features results discovered from a decade long study that shows the significant influence of certain steroid hormone genes and age, on the risk for developing breast cancer. This novel finding shows promise for helping to better predict a women's genetic risk for breast cancer," said Dr. Craig Shimasaki, CEO/President of InterGenetics, the company that developed OncoVue. "Most research has presumed that certain genes confer a constant risk over time, but because of the large population of 6,500 women we studied we were able to see the significant influence age has on breast cancer risk in these genes. Some genes showed increasing risk as a women ages whereas other genes showed decreasing risk over time with age." The OncoVue test incorporates age-specific variation genetic effects to better determine an individual's breast cancer risk." InterGenetics is an Oklahoma-based predictive medicine company.

The *CANCER* article details how InterGenetics' scientists have identified genetic variants in certain steroid hormones whose influence on breast cancer risk vary significantly with the age of the individual.

The findings in this article may be one explanation for the lack of reproducibility in other gene association studies. This discovery could have a significant impact on the application of gene technologies for use in breast cancer prediction, cancer screening, and cancer prevention.

The OncoVue test is easy for women to take; first a simple medical history questionnaire is answered followed by swishing a harmless mouthwash that is returned to a tube. In the InterGenetics' laboratories, DNA from the woman's cheek cells collected in the mouthwash are analyzed using the OncoVue CombiSNP™ technology that looks at a combination of genes, rather than any single gene alone. The knowledge of gene variation is then combined with personal history combinations to determine a woman's individual risk of

developing 'sporadic' breast cancer; the type of breast cancer affecting 90% of all breast cancers in women.

OncoVue gives a woman a better assessment of her future risk of breast cancer to guide her in deciding on surveillance and preventative options based on a comprehensive risk assessment. The OncoVue report assesses a woman's breast cancer risk in three stages of her life; Pre-menopause, Peri-menopause, and Post-menopause and has been developed even for women who do not have a strong family history of cancer, or about 90% of women who get breast cancer.

"Indeed, we hope that our discovery brings us a step closer to the clinical usage of personalized medicine and better assessing breast cancer risk in all women," concluded Dr. Shimasaki.

The OncoVue test has been released at 15 comprehensive breast care centers in the United States under a Food and Drug Administration (FDA) approved Investigational Device Exemption (IDE). The company is currently working with the FDA to obtain final FDA approval for commercial use of OncoVue in the U.S.

OncoVue has been commercially released in the United Kingdom and Ireland under an exclusive agreement with Opaldia, a genetic health service provider with a network of clinics.

### **About InterGenetics**

InterGenetics, is a predictive medicine company emerging as an innovator in the frontier of genetic medicine for cancer to improve women's health through genetics. The company's lead product, the OncoVue® Breast Cancer Risk Test, uses proprietary gene combinations and DNA assessment technology developed by InterGenetics' scientists to quickly and accurately identify women who are at risk of developing breast cancer, potentially many years in advance of their diagnosis, where they can incorporate preventative strategies or catch the disease at its earliest stages where long term survival is the greatest. InterGenetics have a promising research pipeline of predictive tests for other cancers such as ovarian, colon, prostate, and pancreatic cancer. The Company's core research has future application in targeted treatments for pancreatic cancer and end-stage lung cancer. [www.intergenetics.com](http://www.intergenetics.com)

For More Information Contact:

Jane Braden

[jane@goodengroup.com](mailto:jane@goodengroup.com)

405.715.3232